跳转至内容
Merck
CN

SAB1305535

MONOCLONAL ANTI-MYC TAG antibody produced in mouse

clone 9E10, IgG fraction of antiserum, buffered aqueous solution

别名:

Tag from c-Myc protein

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

NACRES:
NA.43
UNSPSC Code:
12352203
Clone:
9E10, monoclonal
Technique(s):
western blot: 1:2,000
Application:
WB
Citations:
14
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

mouse

Quality Segment

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

clone

9E10, monoclonal

form

buffered aqueous solution

technique(s)

western blot: 1:2,000

isotype

IgG1

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

target post-translational modification

unmodified

General description

The cellular myelocytomatosis (c-myc) gene is mapped to human chromosome 8q24. It is the cellular homologue of the v-myc gene originally isolated from an avian myelocytomatosis virus. c-myc is a member of MYC gene family.c-Myc gene codes for basic helix-loop-helix/leucine zipper (bHLH/LZ) transcription factor that regulates the G1-S cell cycle transition.

Application

MONOCLONAL ANTI-MYC TAG antibody produced in mouse has been used in Western blotting.

Biochem/physiol Actions

The cellular myelocytomatosis (c-myc) oncogene plays a vital role in cellular proliferation, differentiation, apoptosis and acts as transcriptional regulator of gene expression. c-myc expression is essential and sufficient to assist most of the cells to enter DNA synthetic (S) phase of the cell cycle. The encoded protein plays a crucial role in vasculogenesis and angiogenesis during cancer development and progression. c-myc interacts with its binding partner Max and activates the transcription of growth promoting genes such as cyclin D2 and ornithine decarboxylase. It also represses the transcription of multiple genes, especially p21 and p27, by binding to the transcription initiator element (Inr) in a complex with Max and either Sp1 or Miz1. Overexpression of MYC in DLBCL (diffuse large B-cell lymphoma) results in poor outcome and invasive treatment when medicated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).

Physical form

Supplied in PBS with 0.09% (W/V) sodium azide

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


Still not finding the right product?

或者

试用我们的 产品选型工具 工具缩小选择范围


存储类别

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库